Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-World Treatment Patterns and Outcomes of Advanced Renal Cell Carcinoma (aRCC) Patients Receiving Nivolumab+Ipilimumab or Pembrolizumab+Lenvatinib in U.S. Oncology Practice

Next Previous
Trial Profile

Real-World Treatment Patterns and Outcomes of Advanced Renal Cell Carcinoma (aRCC) Patients Receiving Nivolumab+Ipilimumab or Pembrolizumab+Lenvatinib in U.S. Oncology Practice

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab/nivolumab (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 23 Aug 2024 Status changed from recruiting to active, no longer recruiting.
  • 05 Apr 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top